Logo image of ARGX.BR

ARGENX SE (ARGX.BR) Stock Fundamental Analysis

EBR:ARGX - Euronext Brussels - NL0010832176 - Common Stock - Currency: EUR

568  +15.4 (+2.79%)

Fundamental Rating

5

Overall ARGX gets a fundamental rating of 5 out of 10. We evaluated ARGX against 71 industry peers in the Biotechnology industry. While ARGX seems to be doing ok healthwise, there are quite some concerns on its profitability. ARGX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

ARGX had positive earnings in the past year.
In the past year ARGX has reported a negative cash flow from operations.
ARGX had negative earnings in 4 of the past 5 years.
ARGX had a negative operating cash flow in each of the past 5 years.
ARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFARGX.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

1.2 Ratios

ARGX's Return On Assets of 13.41% is amongst the best of the industry. ARGX outperforms 94.37% of its industry peers.
The Return On Equity of ARGX (15.13%) is better than 85.92% of its industry peers.
Industry RankSector Rank
ROA 13.41%
ROE 15.13%
ROIC N/A
ROA(3y)-5.24%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.94%
ROIC(3y)N/A
ROIC(5y)N/A
ARGX.BR Yearly ROA, ROE, ROICARGX.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30 -40

1.3 Margins

With an excellent Profit Margin value of 37.99%, ARGX belongs to the best of the industry, outperforming 94.37% of the companies in the same industry.
The Gross Margin of ARGX (89.63%) is better than 87.32% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 37.99%
GM 89.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARGX.BR Yearly Profit, Operating, Gross MarginsARGX.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

6

2. Health

2.1 Basic Checks

ARGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
ARGX has more shares outstanding than it did 1 year ago.
ARGX has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ARGX is higher compared to a year ago.
ARGX.BR Yearly Shares OutstandingARGX.BR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ARGX.BR Yearly Total Debt VS Total AssetsARGX.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

ARGX has an Altman-Z score of 34.64. This indicates that ARGX is financially healthy and has little risk of bankruptcy at the moment.
ARGX has a better Altman-Z score (34.64) than 100.00% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that ARGX is not too dependend on debt financing.
ARGX's Debt to Equity ratio of 0.01 is amongst the best of the industry. ARGX outperforms 87.32% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 34.64
ROIC/WACCN/A
WACC7.57%
ARGX.BR Yearly LT Debt VS Equity VS FCFARGX.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B

2.3 Liquidity

A Current Ratio of 7.29 indicates that ARGX has no problem at all paying its short term obligations.
ARGX has a better Current ratio (7.29) than 90.14% of its industry peers.
ARGX has a Quick Ratio of 6.68. This indicates that ARGX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ARGX (6.68) is better than 88.73% of its industry peers.
Industry RankSector Rank
Current Ratio 7.29
Quick Ratio 6.68
ARGX.BR Yearly Current Assets VS Current LiabilitesARGX.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

More info and screens

8

3. Growth

3.1 Past

ARGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 133.66%, which is quite impressive.
Looking at the last year, ARGX shows a very strong growth in Revenue. The Revenue has grown by 23.34%.
ARGX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 94.61% yearly.
EPS 1Y (TTM)133.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.36%
Revenue 1Y (TTM)23.34%
Revenue growth 3Y63.91%
Revenue growth 5Y94.61%
Sales Q2Q%82.18%

3.2 Future

Based on estimates for the next years, ARGX will show a very strong growth in Earnings Per Share. The EPS will grow by 106.31% on average per year.
ARGX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.13% yearly.
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue Next Year64.13%
Revenue Next 2Y46.91%
Revenue Next 3Y38.91%
Revenue Next 5Y31.13%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ARGX.BR Yearly Revenue VS EstimatesARGX.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
ARGX.BR Yearly EPS VS EstimatesARGX.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 20 40 60 80

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 373.68, ARGX can be considered very expensive at the moment.
Based on the Price/Earnings ratio, ARGX is valued a bit cheaper than the industry average as 77.46% of the companies are valued more expensively.
ARGX's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.88.
With a Price/Forward Earnings ratio of 55.18, ARGX can be considered very expensive at the moment.
80.28% of the companies in the same industry are more expensive than ARGX, based on the Price/Forward Earnings ratio.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.20, ARGX is valued quite expensively.
Industry RankSector Rank
PE 373.68
Fwd PE 55.18
ARGX.BR Price Earnings VS Forward Price EarningsARGX.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ARGX.BR Per share dataARGX.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ARGX's earnings are expected to grow with 155.24% in the coming years.
PEG (NY)0.65
PEG (5Y)N/A
EPS Next 2Y242.7%
EPS Next 3Y155.24%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARGX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARGENX SE

EBR:ARGX (4/30/2025, 7:00:00 PM)

568

+15.4 (+2.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/bmo
Earnings (Next)05-08 2025-05-08/bmo
Inst Owners39.35%
Inst Owner ChangeN/A
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap34.68B
Analysts84
Price Target704.48 (24.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7909.56%
Min EPS beat(2)-38.07%
Max EPS beat(2)15857.2%
EPS beat(4)2
Avg EPS beat(4)3984.41%
Min EPS beat(4)-38.07%
Max EPS beat(4)15857.2%
EPS beat(8)5
Avg EPS beat(8)2003.12%
EPS beat(12)8
Avg EPS beat(12)1344.81%
EPS beat(16)12
Avg EPS beat(16)1027.8%
Revenue beat(2)2
Avg Revenue beat(2)6.37%
Min Revenue beat(2)5.75%
Max Revenue beat(2)6.99%
Revenue beat(4)3
Avg Revenue beat(4)5.41%
Min Revenue beat(4)-0.25%
Max Revenue beat(4)9.17%
Revenue beat(8)7
Avg Revenue beat(8)7.53%
Revenue beat(12)11
Avg Revenue beat(12)27.61%
Revenue beat(16)14
Avg Revenue beat(16)43.67%
PT rev (1m)7.06%
PT rev (3m)17.87%
EPS NQ rev (1m)5.28%
EPS NQ rev (3m)37.7%
EPS NY rev (1m)-0.76%
EPS NY rev (3m)81.3%
Revenue NQ rev (1m)0.94%
Revenue NQ rev (3m)7.74%
Revenue NY rev (1m)1.97%
Revenue NY rev (3m)6.1%
Valuation
Industry RankSector Rank
PE 373.68
Fwd PE 55.18
P/S 18.01
P/FCF N/A
P/OCF N/A
P/B 7.17
P/tB 7.42
EV/EBITDA N/A
EPS(TTM)1.52
EY0.27%
EPS(NY)10.29
Fwd EY1.81%
FCF(TTM)-2.17
FCFYN/A
OCF(TTM)-1.2
OCFYN/A
SpS31.54
BVpS79.19
TBVpS76.58
PEG (NY)0.65
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.41%
ROE 15.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 37.99%
GM 89.63%
FCFM N/A
ROA(3y)-5.24%
ROA(5y)-11.34%
ROE(3y)-5.76%
ROE(5y)-13.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 937.93%
Cap/Sales 3.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.29
Quick Ratio 6.68
Altman-Z 34.64
F-Score2
WACC7.57%
ROIC/WACCN/A
Cap/Depr(3y)606.32%
Cap/Depr(5y)803.99%
Cap/Sales(3y)10.66%
Cap/Sales(5y)13.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)133.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%155.36%
EPS Next Y576.65%
EPS Next 2Y242.7%
EPS Next 3Y155.24%
EPS Next 5Y106.31%
Revenue 1Y (TTM)23.34%
Revenue growth 3Y63.91%
Revenue growth 5Y94.61%
Sales Q2Q%82.18%
Revenue Next Year64.13%
Revenue Next 2Y46.91%
Revenue Next 3Y38.91%
Revenue Next 5Y31.13%
EBIT growth 1Y96.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year959.92%
EBIT Next 3Y190.57%
EBIT Next 5Y115.14%
FCF growth 1Y67.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y80.24%
OCF growth 3YN/A
OCF growth 5YN/A